| Description | CXJ-2, a cyclic peptide, demonstrates moderate affinity for elastin-derived peptides (EDPs) and exhibits potent inhibition of the PI3K/ERK pathway, alongside significant reduction in hepatic stellate cell proliferation and migration, conferring strong antifibrotic efficacy [1]. |
| In vitro | CXJ-2（10 μM, 24 h）以剂量依赖的方式减少了LX2细胞内α-SMA的表达，并显著抑制了LX2细胞的增殖活性[1]。 |
| In vivo | CXJ-2（150 μg/kg，IP（intraperitoneal）注射，qd（每日一次），连续21天）能显著缓解小鼠的肝纤维化症状[1]。同样，CXJ-2（0.1 mg/kg，SC（subcutaneous）注射，单次给药）表现出优良的药代动力学性质[1]。 |
| molecular weight | 1310.37 |
| Molecular formula | C55H87N15O22 |
| CAS | 2919976-92-2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |